A Randomized Open-Label Multi-Centre Active Control Study Investigating the Efficacy and Safety of Imlifidase in Eliminating Donor Specific Anti-HLA Antibodies in the Treatment of Active Antibody-Mediated Rejection in Kidney Transplant Patients
Brief description of study
The purpose of this study is to assess the effectiveness and safety of the study drug, imlifidase in patients who qualify for the study and experience rejection of the kidney graft. This study is designed to test the investigational use of imlifidase compared to standard of care treatment, plasma exchange. Plasma exchange removes and replaces blood plasma: the fluid part of the blood. The drug imlifidase has not been approved by the U.S. Food and Drug Administration. For this reason, it is considered experimental in this study.
Clinical Study Identifier: s17-01814
ClinicalTrials.gov Identifier: NCT03897205
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
